Long-surviving melanoma patients and multiple myeloma patients exhibit reduced CD36 expression on CD8+ T cells and demonstrate responsiveness to programmed cell death 1 (PDCD1, also known as PD-1) treatment. This evidence concerns the gene CD8A and melanoma.